Liver Hormone FGF21 Genetically Linked to Reduced Drinking and Alcohol Liver Disease
Human genetic evidence shows FGF21 signaling curbs harmful drinking behaviors and protects the liver, suggesting a repurposing opportunity for alcohol disorders.
Résumé
Researchers used Mendelian randomization with large genomic datasets to show that genetically higher FGF21 protein levels are associated with fewer binge drinking episodes, reduced alcohol intake, and lower risk of alcohol-related liver disease. FGF21 analogs are already in trials for fatty liver disease, but this study is the first to provide human genetic evidence for their potential in alcohol use disorder. Effects appear to work through behavioral pathways — reduced drinking and improved diet — and increased metabolic rate, rather than direct liver protection alone. A liver-brain axis involving hippocampal and basal ganglia receptors was implicated, and a broad safety analysis across 1,022 traits found a favorable profile.
Résumé détaillé
Alcohol use disorder and alcohol-related liver disease represent major global health burdens with very few approved pharmacotherapies. FGF21, a liver-derived metabolic hormone, is currently in clinical development for metabolic dysfunction-associated steatotic liver disease (MASLD), but its potential role in reducing harmful alcohol use had not been systematically evaluated in humans until now.
This large-scale study leveraged genome-wide association data from four major biobanks — UK Biobank, FinnGen, Million Veterans Program, and GenomALC — encompassing hundreds of thousands of individuals. Using Mendelian randomization (MR), a method that uses genetic variants as natural experiments to infer causal relationships, researchers assessed whether genetically determined FGF21 levels influence problematic alcohol use, binge drinking, and alcohol-related liver disease.
Genetically higher circulating FGF21 was significantly associated with lower problematic alcohol use, fewer binge drinking episodes, reduced weekly drinks, and a 21% lower odds of alcohol-related liver disease. Critically, mediation analyses showed these protective effects were driven by behavioral changes — reduced drinking and improved diet — and higher basal metabolic rate, not direct hepatic mechanisms. A 1-SD increase in hepatic FGF21 expression reduced alcohol-related liver disease risk by 46%.
Receptor-level analyses pointed to hippocampal FGFR3 and basal ganglia β-Klotho (KLB) expression as mechanistic mediators, suggesting a liver-brain signaling axis through which FGF21 modulates reward and consumption behavior. Compared to other MASLD therapeutic targets like PNPLA3 and HSD17B13, FGF21 uniquely reduced alcohol-related outcomes and showed fewer on-target safety liabilities across a phenome-wide scan of 1,022 traits.
These findings position FGF21 analogs as promising dual-action candidates — addressing both the behavioral and hepatic dimensions of alcohol-related disease. The authors advocate for prospective clinical trials and genetic stratification strategies to optimize patient selection.
Principales conclusions
- Genetically higher FGF21 levels linked to 21% lower odds of alcohol-related liver disease (OR=0.79).
- Hepatic FGF21 expression reduced alcohol-related liver disease risk by 46% (OR=0.54) in Mendelian randomization.
- Protective effects were mediated entirely through behavioral pathways: reduced drinking and improved diet.
- Hippocampal FGFR3 and basal ganglia KLB receptor expression implicate a liver-brain signaling axis.
- Phenome-wide scan across 1,022 traits confirmed a favorable safety profile for FGF21 signaling.
Méthodologie
The study used Mendelian randomization across four large GWAS datasets (UK Biobank, FinnGen, MVP, GenomALC) to causally assess FGF21's effects on alcohol behaviors and liver disease. A four-tier framework included multivariable MR, mediation analysis, comparative MR with other MASLD targets, receptor-focused MR using brain-region expression data, and a phenome-wide safety scan across 1,022 traits.
Limites de l'étude
Mendelian randomization relies on assumptions that may not fully hold, including no horizontal pleiotropy. Genetic data were drawn primarily from European-ancestry populations, limiting generalizability to other ethnicities. Only abstract-level data were available; full methodological details could not be verified.
Ce résumé vous a plu ?
Recevez les dernières recherches sur la longévité dans votre boîte de réception chaque semaine.
Saisissez votre e-mail pour vous abonner :